MedTrace Logo

Modulation of Gut Microbiota to Enhance Health and Immunity

NCT04884776 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 453

Last updated 2022-12-29

No results posted yet for this study

Summary

The novel coronavirus infection (COVID-19) caused by the SARS-CoV-2 virus is now a pandemic and has culminated major morbidity and mortality globally. Studies have shown that patients with underlying type 2 diabetes mellitus (DM), obesity, old age and hypertension had a higher risk of developing severe COVID-19 infection and mortality related to COVID-19.Emerging evidence has shown that gut microbiota plays an important role in the pathogenesis of COVID-19.

Conditions

  • Gut Microbiota
  • COVID-19 Vaccine

Interventions

DIETARY_SUPPLEMENT

Microbiome immunity formula

Microbiome immunity formula contains probiotics blend (3 Bifidobacteria, 10 billion CFU per sachet)

DIETARY_SUPPLEMENT

Active placebo

Active placebo contains active vitamin

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Joyce WY Mak, FHKAM · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04884776 on ClinicalTrials.gov